gene editing

Establishment of an efficient in-vitro regeneration system from leaves of Phalaenopsis hybrida cv. ‘Big Chili’

GENESIS-SHIELD: an interpretable ensemble for anomaly detection in CRISPR genomic-workflow security

The rapid advancement of CRISPR-based gene editing has introduced digital-workflow security and integrity challenges: unauthorized modifications, temporal inconsistencies, and duplicated provenance records can compromise the auditability of editing logs. These are distinct from the biological risks of editing its...

CRISPR-Based Mediated Reactivation of Fetal Hemoglobin as a Therapeutic Strategy for Hemoglobinopathies: Evidence from Preclinical to Clinical Trials in Sickle Cell Disease and β-Thalassemia.

Overall, the available evidence suggests that CRISPR-based HbF reactivation is a promising therapeutic approach for β-hemoglobinopathies, although long-term efficacy and safety data remain necessary.

Gene therapy in amyotrophic lateral sclerosis (ALS)

Gene therapy in limb-girdle muscular dystrophy (LGMD)

Graft Biology in the CRISPR Era: From Tissue Fusion to Genome Compatibility

This review synthesizes current advances in embryonic grafting, discusses the molecular basis of graft compatibility and reproductive stability, and highlights key challenges and future research directions for integrating developmental biology with genome editing to improve graft success across wider taxonomic boundari...

Gene therapy in Alzheimer’s disease (AD)

Gene therapy in Huntington’s disease (HD)

Gene therapy in Duchenne muscular dystrophy (DMD)

Multiomics Reveals IGF-1 c.258A > G Reduces Triacylglycerol Containing Medium-Chain Fatty Acid in Milk

Fatty acid composition of milk triacylglycerol (TAG) is important for neonatal growth. We previously identified a synonymous mutation widely distributed in human populations, IGF-1 c.258A > G, which decreased milk TAG content in gene-edited mice. So far, the acyl chain composition of affected TAGs, underlying molecular...

Microbiome–Tumor–Host Interactions in Cancer Therapy: From Chemoresistance Mechanisms to Engineered Living Medicines

This review synthesizes recent advances in pharmaco‐microbiomics, reframing cancer treatment in a hologenetic context, with host, tumor and microbiome acting as a tripartite entity, and establishes microbiome as a predictor and therapeutic target in precision medicine.

CRISPR–Cas9 genome editing: technological advances, delivery strategies and precision engineering of primary cells for therapeutic application in genetic disorders and diabetes mellitus

Recent advances in CRISPR-Cas9–mediated genome editing are highlighted, emphasizing breakthroughs in primary cell editing and the development of translational models for genetic diseases and diabetes mellitus.